Jiangsu Run'an Pharmaceutical Co, Ltd., subsidiaria omnino possessa de Jiangsu Chiatai Qingjiang Pharmaceutical Co, Ltd., modernus summus tech pharmaceuticus societas specialis in R&D, productionis et venditio fertilitatis ordinandae medicinae et varietatis APIs. Project constructionem mense Novembri 2018 incepit, LIX mu aream obtegens, cum tota obsidione 160 decies Yuan et tota area aedificium 25000 quadratum metrorum.
Praecipua activum medicamentum pharmaceuticum (API) producta: Hydrochloridem Gemcitabinum, Celecoxib, bromhexinum hydrochloridum, Iguratimod, Apremilast, Citrate Tofactinib, Crisaborole, Urapidil Hydrochloride, Sugammadex Natrium, Garlicin, Dexmedetomidine Hydrochloride, Rocuronium Bromidum, Finerenone, etc. elit mundi genus facti et productorum gignentium opificem per constantem emendationem et innovationem in technologiarum, et occasiones praeclarum negotium praebent sodalibus nostris per orbem terrarum. Munus nostrum ad praestantes operas emptores nobis permisit ut solidas relationes cum sociis nostris toto orbe extunderet.
Seres operis nomen: Ellamod
Sinensis alias: N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl) methanesulfonamide N-[7-(Methanesulfonamido) -4-oxo-6-phenoxy-4H-chromen-3- y] formamide
Anglicus operis nomen: Iguratimod
CAS#123663-49-0
Formulae hypotheticae: C17H14N2O6S
Pondus hypotheticum: 374.3679
Species et possessiones: cerussa
Adnotationis domesticae numerus API: Y20190021542
Seres Product Name: Ellamod
Seres alias: N [3 (Carboxamido) -4-Oxo-VI-phenoxy-4h-I-Benzopyran-VII-YL] Methanesulfonamide
Latina Product Name: iguratimod
CAS # 123663-49-0
Molecular formula: c17h14n2o6s
Molecular pondus: 374,3679
Specie et proprietates alba pulveris
Domesticis Registration Number API: Y20190021542
Iguratimod API est pro anti-RHEUMATICUS medicamento, Synovitis medicamento.